STAT+: Immunogen study achieves primary goal of shrinking tumors in patients with ovarian cancer
An antibody treatment that delivers a targeted dose of chemotherapy directly to cancer cells shrank…
Category: STAT+
STAT+: Injecting cancer patients with genetically engineered viruses could be a ‘rock star’ therapy. Why hasn’t it taken off?
Stacy Erholtz had run out of options. At the age of 49, she had already…
STAT+: McDonald’s accused of dragging its feet on goal of reducing antibiotic use in beef supplies
Dozens of advocacy groups are accusing McDonald’s (MCD) of failing to follow through on creating…
.jpg)
STAT+: Pharmalittle: Vaccine makers scramble to assess the Omicron Covid strain; Pfizer to step up Covid pill production
Good morning, everyone, and welcome to another working week. We hope the extended weekend break…
STAT+: Alnylam’s new CEO hopes appointment inspires underrepresented groups
Before she accepted a recent offer to become chief executive of Alnylam Pharmaceuticals, Yvonne Greenstreet…
STAT+: Pfizer sues former employee for allegedly stealing Covid-19 vaccine documents
Amid the intense race to develop Covid-19 products, Pfizer (PFE) accused a former employee of…
STAT+: ‘Start at the top’: Women in biotech on how to break down barriers in the industry
Agnieszka Czechowicz remembers what the Magenta Therapeutics website looked like before the biotech startup went…
STAT+: Pharmalittle: Jury finds pharmacy chains recklessly distributed opioids; FDA choice Califf has millions invested in pharma
Hello there, and happy pre-Turkey Day. STAT reporter Andrew Joseph here filling in for Mr….
STAT+: 4 food allergy immunotherapy companies to watch
More and more children are developing food allergies — and biotech companies are springing up…
.jpg)
STAT+: A VC explains why he sees a golden age in health care innovation
One sign you’re living through a golden age is that there’s a lot of gold…
STAT+: Califf, Biden’s pick to lead FDA, has millions invested in pharma and tech companies
WASHINGTON — Robert Califf, President Biden’s choice to lead the Food and Drug Administration, earned…
STAT+: Pharmalittle: Aduhelm study shows brain swelling in one-third of patients; Americans may struggle to access Covid antivirals
Good morning, everyone. Hope you’re powering through this short week before the holiday and aren’t…
STAT+: ‘We all have to come together’: Experts lay out how to keep AI in health care in check
The reach of artificial intelligence in health care settings has expanded to touch everything from…
Talkspace’s leadership exodus leaves behind pressing questions — and a pile of cash
Talkspace, the teletherapy app that went public in a splashy SPAC merger earlier this year,…
STAT+: Private equity firms to acquire Athenahealth for $17 billion
Athenahealth, the Watertown-based electronic health records company, said Monday that it will be acquired for…
STAT+: Pharmalittle: CDC endorses Covid-19 boosters for all adults; investors pressure Novartis to spend cash reserves
Good morning, everyone. Damian Garde here, filling in for Ed Silverman at the start of…
STAT+: Flagship Pioneering’s Noubar Afeyan on the crazy idea behind Moderna and professional entrepreneurs
On his desk — placed so its visible on his Zoom calls — Flagship Pioneering…
STAT+: Verily’s Amy Abernethy hints at clinical trial blueprint for 2022
Verily’s quest to become a major player in the life sciences has resulted in a…
STAT+: Pharmalittle: FDA expands emergency use for Pfizer and Moderna Covid boosters; Biden move to lower drug prices would save U.S. $160 billion
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Watch: Experts challenge Eli Lilly exec on effectiveness of Alzheimer’s drug
Months after the Food and Drug Administration approved Biogen’s Alzheimer’s drug Aduhelm, Eli Lilly hopes…
STAT+: Big data is the next frontier for biotech — and they’re scrambling for data scientists
Nikhil Munshi’s lab at the Dana-Farber Cancer Institute has accumulated an overwhelming amount of data…
STAT+: Can local governments convince the courts that opioid makers and wholesalers caused a public nuisance?
Earlier this week, the state of Washington went to trial relying on a controversial legal…
STAT+: GlaxoSmithKline’s Emma Walmsley predicts a ‘landmark’ 2022 for the company
Next year will be a “landmark” one for GlaxoSmithKline, according to CEO Emma Walmsley —…
STAT+: Proposal to waive intellectual property rights for Covid-19 vaccines and drugs appears unlikely to pass
A controversial proposal for the World Trade Organization to temporarily waive intellectual property rights and…
STAT+: Former DARPA director: Biden’s new science agency should be independent, not an NIH office
WASHINGTON — The former director of DARPA, the Pentagon’s high-stakes research arm, says that for…
STAT+: A lack of access: Pharma is failing to ensure new antibiotics will be available to poor countries, analysis finds
Although the pharmaceutical industry is making modest progress in countering resistance to superbugs, drug companies…
STAT+: Generate Biomedicines raises $370m and plans to increase workforce sixfold
Cambridge biotech Generate Biomedicines said Thursday it has raised $370 million in venture capital from…
STAT+: Pharmalittle: SEC probes Cassava over Alzheimer’s drug results; Teva takes pharma in a new direction with a bond sale
Rise and shine, everyone. Another busy day is on the way. We can tell because…
STAT+: By selling bonds tied to drug access and climate goals, Teva takes pharma in a new direction
In a first-of-its-kind move by a drug maker, Teva Pharmaceuticals (TEVA) recently sold $5 billion…
STAT+: Gilead licenses cancer drugs from Arcus in potentially lucrative but risky bet on its cancer business
Gilead Sciences said Thursday that it has exercised an option to license four cancer drugs…
STAT+: Set to retire, Alnylam’s Maraganore reflects on his successor and his next steps
John Maraganore’s decision to step down as Alnylam Pharmaceuticals’ CEO after almost 20 years came…
STAT+: ‘Late is better than never’: Biden plan to boost U.S. production of Covid vaccines gets mixed reviews
Under pressure to widen global access to Covid-19 vaccines, the Biden administration plans to invest…
STAT+: ‘Can’t get much worse:’ What a European rejection of an Alzheimer’s drug would mean for Biogen
In a potentially huge setback for Biogen (BIIB), a European regulatory panel signaled that it…
STAT+: Pharmalittle: European regulators unlikely to approve Biogen Alzheimer’s drug; U.S. to invest billions to expand Covid vaccine production
Hello, everyone, and welcome to the middle of the week. You made it this far,…
STAT+: European regulators signal Biogen’s new Alzheimer’s therapy is unlikely to win approval
A panel of European drug reviewers notified Biogen that its Alzheimer’s treatment Aduhelm is unlikely…
STAT+: ‘Where’s my prescription?’: California wants to revoke an OptumRx pharmacy license for prescribing lapses
The California Board of Pharmacy is seeking to revoke or suspend a pharmacy license held…
STAT+: Pharmalittle: Biogen R&D chief retiring amid controversy over Alzheimer’s drug; Pfizer strikes deal for generic versions of its Covid pill
Top of the morning to you, and a fine one it is. Crystal clear blue…
STAT+: The prices of 7 drugs were hiked without proof of new benefits, costing the U.S. $1.6 billion in 2020
During 2020, drug makers raised prices on seven widely used medicines by substantial amounts without…
STAT+: Like Merck, Pfizer strikes a licensing deal with the Medicines Patent Pool for a Covid-19 pill
Amid considerable anticipation over its Covid-19 pill, Pfizer (PFE) reached a licensing agreement with the…
STAT+: ‘It’s going to set the bar pretty high’: A path forward for trusted AI in breast cancer risk prediction
As the role of artificial intelligence grows in medicine, one of the leading concerns is…
STAT+: How America’s largest Catholic hospital system is moonlighting as a private equity firm
The nation’s largest Catholic hospital system, a sprawling behemoth of more than 140 hospitals called…
STAT+: In a sudden move, Al Sandrock, the man behind Biogen’s Aduhelm, to retire
Al Sandrock, Biogen’s top scientist and the face of its years-long campaign to develop a…
STAT+: Conflicts of interest exist among editors and authors of widely used psychopharmacology textbooks
Amid ongoing concerns over conflicts of interest that may affect medical practice, a new analysis…
STAT+: Biogen’s pricey Alzheimer’s drug will fuel record premium hikes for Medicare Part B
The high cost of the Alzheimer’s drug from Biogen (BIIB) is a key reason that…
STAT+: Pharmalittle: Califf has lots of unfinished FDA business; FDA’s warnings prompt trial sponsors to report results
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: When FDA rattles its sabre, drug makers and universities start reporting overdue trial results
Over the past eight years, more than 90% of drug makers and universities that received…
STAT+: Pharmalittle: J&J to split into two companies; AstraZeneca will price its Covid-19 vaccine to make it profitable
And so, another working week will soon draw to a close. Not a moment too…
STAT+: 5 health tech startups targeting the Medicaid population to watch
When it comes to new opportunities, health tech companies tend to follow the money. That…
STAT+: Startup Spotlight: Rectify is hoping it can mend broken ABC transporters, starting in the liver
A former Vertex scientist is setting his sights on an entire family of transporter proteins…
STAT+: ‘A work in progress’: BioNTech’s CEO wants to widen Covid-19 vaccine access on his own terms
Two years ago, Ugur Sahin was an under-the-radar but extremely determined scientist running a company…